Branham Law, LLP Investigates AMAG Pharmaceuticals on Behalf of Stockholders

Before you go, we thought you'd like these...
Before you go close icon

Branham Law, LLP Investigates AMAG Pharmaceuticals on Behalf of Stockholders

DALLAS--(BUSINESS WIRE)-- Branham Law, LLP announces that it is investigating AMAG Pharmaceuticals (NASDAQ: AMAG) and certain of its officers and directors for potential breaches of fiduciary duties in connection with AMAG's apparent failure to disclose that users of the Company's primary drug, Feraheme had suffered adverse reactions, including hospitalizations and one possible death.


Investors who purchased AMAG stock before January 1, 2010 and have held AMAG stock since, or anyone with information about this investigation should contact Branham Law, LLP at tbranham@branham-law.com or call (855) 722-5910.

On February 4, 2013, the United States First Circuit Court of Appeals reversed the district court's dismissal of these claims and reinstated the action. After these failures to disclose were revealed, AMAG's stock fell over $7.00 per share. Subsequent disclosures regarding the company's rebate program resulted in a further drop of $4.02 per share.

Contact Trey Branham, Branham Law, LLP, 1-855-722-5910, 3900 Elm Street, Dallas, Texas 75226 for additional information.



Branham Law, LLP
Trey Branham, 214-722-5990
www.branham-law.com

KEYWORDS:   United States  North America  Texas

INDUSTRY KEYWORDS:

The article Branham Law, LLP Investigates AMAG Pharmaceuticals on Behalf of Stockholders originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners